Ronald E. Polk - Concepedia

Author

Ronald E. Polk

Virginia Commonwealth University Medical Center

Also Known As

Mark H Wilcox, R Polk, R. E. Polk, Ronald E Polk, Ronald E. Polk, Ronald Polk

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Virginia Commonwealth University Medical Center Virginia Commonwealth University University HealthSystem Consortium Research Triangle Park Foundation University of Maryland, Baltimore

About

Ronald E. Polk is an author at Virginia Commonwealth University Medical Center specializing in medicine, drug resistance, and antibiotics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	628
2	Health Sciences	5	5	241
3	Epidemiology	2	2	162
4	Education	1	1	55
5	Emergency Medicine	1	1	11

Ronald E. Polk

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Measurement of Adult Antibacterial Drug Use in 130 US Hospitals: Comparison of Defined Daily Dose and Days of Therapy Ronald E. Polk, C. Fox, Alison Mahoney, Clinical Infectious Diseases	2007	409
Vancomycin and the Red-Man Syndrome: Pharmacodynamics of Histamine Release Ronald E. Polk, Daniel P. Healy, Lawrence B. Schwartz, The Journal of Infectious Diseases Pharmacological StudyAntibioticsMedicineFirst InfusionPharmacology	1988	186
Hospital and Community Fluoroquinolone Use and Resistance in Staphylococcus aureus and Escherichia coli in 17 US Hospitals Conan MacDougall, James Patrick Powell, C. K. Johnson, Clinical Infectious Diseases	2005	173
Trends in Antibacterial Use in US Academic Health Centers Amy Pakyz, Conan MacDougall, Michael Oinonen, Archives of Internal Medicine	2008	162
Relationship of Carbapenem Restriction in 22 University Teaching Hospitals to Carbapenem Use and Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Amy Pakyz, Michael Oinonen, Ronald E. Polk Antimicrobial Agents and Chemotherapy Antibiotic ResistanceDrug ResistanceUniversity Teaching HospitalsAntimicrobial StewardshipCarbapenem Restriction	2009	148
Predicting Hospital Rates of Fluoroquinolone-Resistant Pseudomonas aeruginosa from Fluoroquinolone Use in US Hospitals and Their Surrounding Communities Ronald E. Polk, C. K. Johnson, Donna K. McClish, Clinical Infectious Diseases	2004	117
Pharmacokinetics of [ <sup>14</sup> C]Abacavir, a Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitor, Administered in a Single Oral Dose to HIV-1-Infected Adults: a Mass Balance Study James A. McDowell, Gregory E. Chittick, Joshua Ravitch, Antimicrobial Agents and Chemotherapy Reverse Transcriptase InhibitorImmunologyPharmacotherapyAntiviral DrugHuman Immunodeficiency Virus	1999	97
Variability in Rates of Use of Antibacterials Among 130 US Hospitals and Risk-Adjustment Models for Interhospital Comparison Conan MacDougall, Ronald E. Polk Infection Control and Hospital Epidemiology	2008	72
Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males Ronald E. Polk, Donald F. Brophy, Debra S. Israel, Antimicrobial Agents and Chemotherapy	2001	70
Perceived Barriers to Scholarship and Research Among Pharmacy Practice Faculty: Survey Report from the AACP Scholarship/Research Faculty Development Task Force Jessica Robles, Sharon L. Youmans, Debbie C. Byrd, American Journal of Pharmaceutical Education Family MedicinePharmacy Practice FacultyFaculty IssueSurvey ReportPharmaceutical Practice	2009	55

Page 1